Core Insights - Century Therapeutics has appointed Dr. Han Lee and Dr. Martin Murphy to its Board of Directors, enhancing its leadership team at a critical time for the company [1][2] Company Overview - Century Therapeutics is a biotechnology company focused on developing induced pluripotent stem cell (iPSC)-derived cell therapies aimed at treating autoimmune diseases and cancer [4] - The company utilizes its iPSC cell foundry and a novel immune evasion engineering technology called Allo-Evasion™ to create off-the-shelf cell therapies, which are expected to improve patient access and offer advantages over existing therapies [4] Leadership Appointments - Dr. Han Lee will serve on the Audit and Compensation Committees, bringing extensive experience in capital formation and corporate development from his previous roles at ImmPACT Bio, Neogene Therapeutics, and AstraZeneca [1][2] - Dr. Martin Murphy will be part of the Compensation and Nominating and Corporate Governance Committees, with a strong background in life science investment and company creation from his roles at Syncona and MVM Life Science Partners [1][3] Strategic Focus - The company is prioritizing the advancement of its iPSC-derived cell therapy programs, particularly CNTY-813, which is being developed as a potentially curative treatment for type 1 diabetes [2]

Core Insights - Century Therapeutics is advancing its iPSC-derived cell therapies targeting autoimmune diseases and cancer, with a focus on Type 1 diabetes (T1D) and B-cell-mediated diseases [2][5][6] Business Update - The company announced its lead iPSC-derived beta islet program for T1D, with plans to initiate IND-enabling studies by the end of 2025 and submit an IND as early as 2026 [2][5][6] - CNTY-308 is progressing through IND-enabling studies, aiming for clinical study initiation in 2026 [5][6] - CNTY-101 is continuing in a Phase 1/2 investigator-sponsored trial, with initial clinical data expected in December 2025 [6] Financial Results - As of September 30, 2025, cash, cash equivalents, and marketable securities totaled $132.7 million, down from $220.1 million at the end of 2024, with an estimated cash runway into Q4 2027 [6][10] - R&D expenses for Q3 2025 were $22.5 million, a decrease from $27.2 million in Q3 2024, primarily due to reduced personnel and manufacturing costs [6][10] - G&A expenses were $6.8 million for Q3 2025, down from $8.4 million in Q3 2024, attributed to a gain on lease modification [10] - The net loss for Q3 2025 was $34.4 million, compared to a net loss of $31.2 million for the same period in 2024 [10][13]